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Abstract. Background: Phenothiazines have anticancer
properties and are able to reverse the multidrug resistance
of neoplastic cells by inhibiting the ATP-binding cassette,
sub-family B (MDR/TAP), member 1 protein (ABCB1 or P-
glycoprotein) activity. Materials and Methods: A series of
new phenothiazine derivatives was investigated regarding
their ABCB1-modulating effect on multidrug resistant mouse
T-lymphoma cells by rhodamine 123 accumulation assay and
real-time ethidium bromide accumulation assay. Results: The
phenothiazine derivatives exhibited a potent anticancer effect
on the parental cell line and on its multidrug-resistant mouse
T-lymphoma subline overexpressing the ABCB1 transporter.
The inhibition of the ABCB1 transporter in the presence of
the newly-developed phenothiazines was greater than that for
the known ABCB1 inhibitors thioridazine and verapamil.
Conclusion: Based on the chemical structures and biological
activity, compounds with bivalent sulfur atom in the
phenothiazine ring demonstrated marked ABCB1-modulating
effect, however, other derivatives with halogen or amide
substitutions were ineffective.
Phenothiazines have been in use for the treatment of
psychiatric disorders since the 1950s. Other pharmacological
and biological activities of phenothiazines have since been
described, such as anti-bacterial (1), anti-mycobacterial (2),
anti-plasmid (3) and immunomodulatory (4) effects.
Phenothiazines and structurally related compounds can
sensitize multidrug-resistant (MDR) cells to chemotherapeutics
(5). Phenothiazines mostly substituted at position 10 with
dialkylaminoalkyl groups, and additionally at position 2 with
small groups, exhibit valuable activities such as neuroleptic,
anti-emetic, anti-histaminic, anti-puritic, analgesic and anti-
helmintic (6). The introduction of different substituents into the
phenothiazine skeleton, as well as the modification of the
tricyclic ring system, alters their biological activities (7). In
addition numerous derivatives of phenothiazine for similar
applications have been synthesized and patented (8). 
Recently, a series of phenothiazine derivatives was
investigated regarding their inhibitory activity against bacterial
efflux pump systems. As structures of the studied series of
phenothiazines differ from each other by slight modifications,
it was relatively easy to observe the structure−activity
relationship based on the efflux pump inhibitory properties of
the derivatives (9).
A number of cellular mechanisms are responsible for the
MDR of cancer cells. The most common mechanism that
reduces the efficacy of anticancer agents is the overexpression
of ATP-binding cassette (ABC) drug transporters (10).
Phenothiazines are able to reverse the MDR of neoplastic cells
to cytostatic drugs. The lipophilic nature of phenothiazines
enables them to easily-penetrate the cell membrane (11).
The presence of the 2-butanol chain is essential in regard
to modulation of the ABCB1 protein (P-glycoprotein) by
alkylphenothiazines, furthermore the lack of a hydroxyl
group significantly reduces the rate of inhibition (12).
The present study provides information regarding this series
of new phenothiazine derivatives regarding their ABCB1-
modulating effect on MDR mouse T-lymphoma cells.
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Materials and Methods
Compounds. Chemical structures of the tested 26 phenothiazine
derivatives are shown in Figure 1, with the aid of Tables I and II.
The compounds in Table I were prepared by recently elaborated
chemical transformations (12). Thus, derivatives 1a-o were obtained
by protection and Buchwald-Hartwig amination of 1, where R=Cl,
whereas compound 2 was obtained as a by-product of the
hydroboration-oxidation transformation of the appropriately-
substituted dienylphenothiazine (13). Sulfoxides 3a-e and sulfones
3f-j (Table II) were prepared by oxidation of the related
phenothiazine 1 with m-chloroperoxybenzoic acid (12). The
phenothiazine derivatives were dissolved in dimethyl sulfoxide
(DMSO; Sigma, Madrid, Spain). Ethidium bromide (EB) was
purchased from Sigma.
Cell lines. L5178Y parental mouse T-cell lymphoma cells (ECACC
cat. no. 87111908; U.S. FDA, Silver Spring, MD, USA) were
transfected with pHa MDR1/A retrovirus (14, 15). Τhe ABCB1-
expressing cell line was selected by culturing the transfected cells
with 60 ng/ml of colchicine (Sigma-Aldrich Chemie GmbH,
Steinheim, Germany) to maintain the MDR phenotype using
McCoy’s 5A medium (Sigma) supplemented with L-glutamine
(Sigma) and antibiotics (penicillin/streptomycin solution, Sigma) at
37˚C and in an atmosphere with 5% CO2.
Assay for antiproliferative and cytotoxic effect. The effects of
increasing concentrations of the compounds on cell growth were
tested in 96-well flat-bottomed microtiter plates. The compounds
were diluted in 100 μl medium, then 6×103 cells for antiproliferative
assay, or 2×104 cells for cytotoxic assay in 50 μl of medium,
respectively, were added to each well, with the exception of the
medium control wells. The culture plates were further incubated at
37˚C for 72 and 24 h, respectively; at the end of the incubation
period, 15 μl of 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT, Sigma-Aldrich Chemie GmbH) solution
(from a 5 mg/ml stock) were added to each well. After incubation at
37˚C for 4 h, 100 μl of sodium dodecyl sulfate (SDS) (Sigma)
solution (10% in 0.01 M HCI) were added to each well and the
plates were further incubated at 37˚C overnight. The cell growth
was then determined by measuring the optical density (OD) at 550
nm (ref. 630 nm) with a Multiscan EX ELISA reader (Thermo
Labsystems, Cheshire, WA, USA).
Inhibition of cell growth was determined according to the formula:
Where IC50 is defined as the inhibitory dose that reduces the growth
of the compound-treated cells by 50%. 
Statistical analyses were conducted using the Student’s t-test. The
accepted level of significance was p<0.05. The analyses were
performed using GraphPad Prism software (GraphPad Software, Inc.
7825 Fay Avenue, Suite 230 La Jolla, CA 92037 USA). 
Flow cytometry assay for evaluation of a compound on the retention
of rhodamine 123 by MDR mouse T-cell lymphoma cells. This assay
has been fully described elsewhere (16). Briefly, the cells were
adjusted to a density of 2×106/ml, re-suspended in serum-free
McCoy’s 5A medium and distributed in 0.5 ml aliquots into
Eppendorf centrifuge tubes. Test compounds (10 μl) were added at
different concentrations (0.2-10 μM), and the samples were
incubated for 10 min at room temperature. Next, 10 μl (5.2 mM
final concentration) of rhodamine 123 were added to the samples
and the cells were incubated for a further 20 min at 37˚C, washed
twice and re-suspended in 0.5 ml phosphate-buffered saline (PBS)
for analysis. The fluorescence of the cell population was measured
with a Partec CyFlow flow cytometer (Partec, Münster, Germany).
Verapamil was used as a positive control (17) in the rhodamine 123
exclusion experiments. The ratio of the mean fluorescence intensity
was calculated for the treated MDR and parental cell lines as
compared to untreated cells. A fluorescence activity ratio (FAR) was
calculated via the following equation, on the basis of the measured
fluorescence values:
The results provided are from a representative flow cytometric
experiment in which 10,000 individual cells were evaluated. Partec
CyFlow flow cytometer research software was used to analyze the
recorded data. The data were first presented as histograms and the
data were converted to FAR units that define fluorescence intensity,
standard deviation, peak channel in the total and in the gated
populations. 
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Figure 1. Structures of N-hydroxyalkyl-2-aminophenothiazines (1a-o, 2, 3a-j). 
EB accumulation assay. The cells were adjusted to a density of 2×106
cells/ml, centrifuged at 2000 ×g for 2 min and re-suspended in PBS at
pH 7.4. The cell suspension was distributed in 90 μl aliquots into 0.2
ml tubes. The tested phenothiazines were individually added at
different concentrations in 5 μl of their stock solutions and the
samples were then incubated for 10 minutes at 25˚C. Verapamil was
used as a positive control (17). After this incubation, 5 μl (1 μg/ml
final concentration) of EB (20 μg/ml stock solution) were added to
the samples and the tubes were placed in a Rotor-Gene 3000™
thermocycler with real-time analysis software (Corbett Research,
Sydney, Australia) and the fluorescence monitored on a real-time
basis. Prior to the assay, the instrument was programmed for
temperature (37˚C), appropriate excitation and emission wavelengths
of EB (530 nm bandpass and 585 nm highpass, respectively), and the
time and number of cycles for the recording of the fluorescence (18).
The results were evaluated by Rotor-Gene Analysis Software 6.1
(Build 93) provided by Corbett Research.
Results
The derivatives inhibited cell proliferation (IC50≈1.5 μM),
but the difference between the parental and MDR cells
overexpressing ABCB1 was not significant (Student’s t-test,
p>0.05). In addition, the IC50 values of cytotoxicity were
similar for the parental and MDR cells (IC50≈5 μM)
(Student’s t-test, p>0.05).
ABCB1-modulating properties were evaluated by
comparing the accumulation of the specific fluorescent
substrate of ABCB1, rhodamine-123, in MDR cells, where
P-glycoprotein expression is high with that in parental cells.
The resulting FAR values are summarized in Table III.
Compounds with FAR values greater than 1 were considered
to be active P-glycoprotein inhibitors, and those with FAR
values greater than 10 as strong MDR modulators.
All the phenothiazines investigated in the present study
inhibited the activity of P-glycoprotein, and based on the
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Table I. Substituents of N-hydroxyalkyl-2-aminophenothiazines (1a-o). 
Table II. Substituted sulfoxide and sulfone derivatives of N-hydroxyalkyl-
2 aminophenothiazines (3a-j).
FARs, the most potent derivatives were 1c, 1g, 1j, 1k, 1f, 1h,
1d, 3f, and 3i (Table III). These compounds were able to
reverse the P-glycoprotein-related resistance of MDR cells
and exhibited remarkable effects at low concentration (0.2
μM) by increasing the intracellular accumulation of the
ABCB1 substrate rhodamine 123 (FAR=3.12-6.8 at 0.2 μM
concentration). The derivatives 1k, 1j, 1g, 1m, 1c
(FAR=77.29-50.01), and 1o, 1f, 1l, 1d, 1a, 3i, 1b, 2, 3f and
1n, were found to be active ABCB1 inhibitors at the
concentration of 2 μM (FAR=43.94-30.36).
To demonstrate the efficacy of these new derivatives, an
example is depicted in Figure 2, namely the ABCB1-
modulating effect of compound 1a compared to the activity
of well-known ABCB1-inhibiting agents verapamil and
thioridazine. The real-time accumulation of the ABCB1
substrate EB in the presence of resistance modifiers was
monitored. As shown by Figure 2, compound 1a had greater
effect on MDR mouse T-lymphoma cells than verapamil and
thioridazine.
Discussion
Compounds that inhibit the function of MDR efflux proteins
might improve the cytotoxic activity of anticancer
chemotherapy, for this reason, systematic research for
pharmacophor structures is a promising strategy aiming to
increase the efficacy of drugs against ABCB1-related MDR
in cancer. In the present study, a series of new phenothiazine
derivatives was developed and systematically evaluated.
It is well-known that phenothiazines have ABCB1-modulatory
effects (5, 19, 20), as well as anti-bacterial, anti-fungal, anti-
cancer, anti-viral, anti-inflammatory, anti-malarial, anti-filarial,
trypanocidal, anti-convulsant, analgesic, immunosuppressive and
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Table III. Rhodamine123 accumulation in multidrug-resistant mouse T-
lymphoma cells overexpressing the ATP-binding cassette transporter
protein B1.
Compound Concentration (μM) Fluorescence activity ratio
Verapamil 20.4 8.63
1 a 0.2 0.93
2 35.32
1 b 0.2 1.61
2 32.28
1 c 0.2 6.81
2 50.01
1 d 0.2 3.58
2 36.83
1 e 0.2 1.73
2 29.13
1 f 0.2 5.90
2 40.47
1 g 0.2 3.93
2 54.34
1 h 0.2 3.37
2 5.88
1 i 0.2 1.91
2 23.25
1 j 0.2 4.24
2 71.87
1 k 0.2 3.88
2 77.29
1 l 0.2 1.15
2 39.89
1 m 0.2 1.25
2 50.78
1 n 0.2 1.35
2 30.36




3 a 0.2 0.80
2 1.70
3 b 0.2 0.67
2 16.34
3 c 0.2 0.79
2 10.19
3 d 0.2 1.22
2 26.79
3 e 0.2 1.03
2 6.58
3 f 0.2 0.97
2 14.68
3 g 0.2 3.13
2 30.79
3 h 0.2 1.49
2 21.3
3 i 0.2 3.12
2 32.9
3 j 0.2 0.93
2 21.10
Figure 2. Comparison of ethidium bromide accumulation by multidrug-
resistant mouse T-lymphoma cells overexpressing the ATP-binding
cassette transporter protein B1 in the presence of thioridazine (TZ),
verapamil (VP), and the phenothiazine derivative 1a. The graphs were
obtained from a single monitoring by the fluorescence assay.
MDR-reversal properties. The reasons for the biological effects
of phenothiazines are the interactions of the pharmacophoric
substituent and interaction of the multicyclic ring system (π–π
interaction, DNA-intercalating properties); in addition their
lipophilic character facilitates their penetration through
biological membranes (7).
In the present work, 26 new phenothiazine derivatives
were investigated and all of them had potent antiproliferative
and cytotoxic effect. Furthermore, they inhibited the activity
of the ABCB1 transporter (P-glycoprotein), and this
inhibition was greater than that of the well-known ABCB1
inhibitors thioridazine and verapamil.
Comparison of structures with their biological efficacy in the
case of compounds with bivalent sulfur atom in the
phenothiazine ring reveals that all derivatives exhibited marked
ABCB1-modulatory effects due to the presence of a secondary
amine moiety, whereas other derivatives, e.g. halogen- or
amide-substituted compounds seem to be ineffective. With
sulfoxides and sulfones, however, such a relationship was not
apparent.
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